Stroke drug trial hopes to reduce disability with Anti-Inflammatory

NCT ID NCT07509645

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding tocilizumab, an anti-inflammatory drug, to standard emergency stroke treatment improves outcomes for people with a severe stroke in the back of the brain. About 348 adults will receive either tocilizumab or a placebo by IV right before a procedure to reopen blocked arteries. The main goal is to see if more people can function independently at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tocilizumab (a drug that blocks interleukin-6, a protein involved in inflammation)
What this could lead to
If it works, this could lead to a new treatment that reduces disability after a severe stroke in the back of the brain.
What could go wrong
This is a mid-stage trial with 348 people, so results may not apply to all stroke patients. Tocilizumab can increase infection risk, and the benefit over standard care is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE DUE TO BASILAR ARTERY OCCLUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Anyang People's Hospital

    RECRUITING

    Anyang, Henan, 455000, China

    Contact

  • Capital Medical Univercity Xuanwu Hospital

    RECRUITING

    Beijing, 100053, China

  • Lishui Central Hospital

    RECRUITING

    Lishui, Zhejiang, 323000, China

    Contact

  • Nanyang Central Hospital

    RECRUITING

    Nanyang, Henan, 473000, China

    Contact

  • People's Hospital of Linyi

    RECRUITING

    Linyi, Shandong, 276000, China

    Contact

  • People's Hospital of Xihua

    RECRUITING

    Zhoukou, Henan, 466600, China

    Contact

  • People's Hospital of Yueqing

    RECRUITING

    Yueqing, Zhejiang, 325600, China

    Contact

  • Suzhou Municipal Hospital

    RECRUITING

    Suzhou, Anhui, 234000, China

    Contact

  • Taizhou enze Hospital

    RECRUITING

    Taizhou, Zhejiang, 318000, China

    Contact

  • The First Affiliated Hospital of Henan Medical University

    RECRUITING

    Xinxiang, Henan, 453000, China

    Contact

  • Xianyang First People's Hospital

    RECRUITING

    Xianyang, Shanxi, 712000, China

    Contact

  • Yuncheng Central Hospital

    RECRUITING

    Yuncheng, Shanxi, 044000, China

    Contact

  • Zibo Central Hospital

    RECRUITING

    Zibo, Shandong, 255000, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.